CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists

被引：0
|
作者：
Miller, MD
Lineberger, JE
Dornadula, G
Danzeisen, RC
Blau, CR
Danovich, RM
Miller, MA
Finke, PE
Oates, BD
Caldwell, CG
Chen, P
Meurer, LC
Mills, SG
Springer, MS
Petropoulos, CJ
Whitcomb, J
Huang, W
Fransen, S
Simon, AJ
Hazuda, DJ
机构：
[1] Merck Res Labs, Dept Biol Chem, West Point, PA USA
[2] Merck Res Labs, Dept Microbial Vaccine Res, West Point, PA USA
[3] Dept Med Chem, Rahway, NJ USA
[4] Dept Immunol & Rheumatol, Rahway, NJ USA
[5] ViroLog Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2003年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
61
引用
收藏
页码：U66 / U67
页数：2
相关论文
共 50 条
  • [31] Recent advances of CCR5 antagonists
    Baba, Masanori
    CURRENT OPINION IN HIV AND AIDS, 2006, 1 (05) : 367 - 372
  • [32] Combinatorial synthesis of CCR5 antagonists
    Willoughby, CA
    Berk, SC
    Rosauer, KG
    Degrado, S
    Chapman, KT
    Gould, SL
    Springer, MS
    Malkowitz, L
    Schleif, WA
    Hazuda, D
    Miller, M
    Kessler, J
    Danzeisen, R
    Holmes, K
    Lineberger, J
    Carella, A
    Carver, G
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (24) : 3137 - 3141
  • [33] CCR5 antagonists with anti-HIV activity: Is inhibition on the cell surface sufficient?
    Springer, M
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135
  • [34] Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
    Kondru, Rama
    Zhang, Jun
    Ji, Changhua
    Mirzadegan, Tara
    Rotstein, David
    Sankuratri, Surya
    Dioszegi, Marianna
    MOLECULAR PHARMACOLOGY, 2008, 73 (03) : 789 - 800
  • [35] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S13 - S13
  • [36] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 : S13 - S13
  • [37] Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
    Berro, Reem
    Sanders, Rogier W.
    Lu, Min
    Klasse, Per J.
    Moore, John P.
    PLOS PATHOGENS, 2009, 5 (08)
  • [38] Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
    Kim, D
    Wang, LP
    Caldwell, CG
    Chen, P
    Finke, PE
    Oates, B
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Gould, SL
    DeMartino, JA
    Springer, MS
    Hazuda, D
    Miller, M
    Kessler, J
    Danzeisen, R
    Carver, G
    Carella, A
    Holmes, K
    Lineberger, J
    Schleif, WA
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (24) : 3099 - 3102
  • [39] Serious doubts on safety and efficacy of CCR5 antagonists CCR5 antagonists teeter on a knife-edge
    Horster, S.
    Goebel, F. D.
    INFECTION, 2006, 34 (02) : 110 - 113
  • [40] HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
    Pfaff, Jennifer M.
    Wilen, Craig B.
    Harrison, Jessamina E.
    Demarest, James F.
    Lee, Benhur
    Doms, Robert W.
    Tilton, John C.
    JOURNAL OF VIROLOGY, 2010, 84 (13) : 6505 - 6514
12345